Pharmaceutical giant Pfizer close to reach $9b deal with Nestle

Pharmaceutical giant Pfizer close to reach $9b deal with Nestle

PanARMENIAN.Net - U.S. pharmaceutical giant Pfizer is close to reaching a $9 billion deal to sell its infant nutrition business to Nestle, AFP reports citing the Wall Street Journal.

The Journal said Nestle, the Swiss food giant, had apparently beaten out Groupe Danone and Mead Johnson Nutrition, which had considered a joint bid for the business, and that the final deal could be announced next week.

A Pfizer spokeswoman contacted by AFP refused to comment on the report, saying "no decisions have been made at this point" on the sale of the infant nutrition business or an animal health business also set to be auctioned off.

"The animal health and nutrition businesses are highly valued assets, and our decision about strategic options will be driven by value creation and delivering the best after-tax value for our shareholders," she said.

Pfizer has moved to unload peripheral entities in recent months in order to focus on its core medicine business.

In November its patent on the best-selling drug of all time, the cholesterol-lowering medication Lipitor, expired, opening the path to generic competitors for America's most popular medication.

 Top stories
This year’s event will be held in Yerevan under the motto “16 Countries … and Opportunities for Enterprise Development.”
“Government’s policy line of boosting the NPP’s safety and building a new power unit remains unchanged,” Armen Movsisyan said.
Armenia’s rich cultural, historical and Christian heritage will be presented in travel guides and maps in Russian during the exhibition.
The contract terms stipulated by companies allowed them to charge subscribers for the period when no internet service was provided.
Partner news